HALO Earnings

Quarterly EPS
$1.08
Q3 2024
$1.08
Q4 2024
$0.96
Q1 2025
$1.36
Q2 2025
$1.49
Q3 2025
$-1.20
Q4 2025
$1.27
Q1 2026
$1.96
Q2 2026
Latest Revenue481.0M
Latest Net Income229.9M
EPS & Revenue Trend
PeriodEPSRevenueNet IncomeRev YoYEPS YoY
Q2 2026$1.96481.0M229.9M+47.7%+44.1%
Q1 2026$1.27376.7M150.0M+42.2%+32.3%
Q4 2025-$1.20451.8M-141591000+51.6%-211.1%
Q3 2025$1.49354.3M175.2M+22.1%+38.0%
Q2 2025$1.36325.7M165.2M+40.8%+86.3%
Q1 2025$0.96264.9M118.1M+35.2%+57.4%
Q4 2024$1.08298.0M137.0M+29.5%+63.6%
Q3 2024$1.08290.1M137.0M+34.3%+74.2%
Q2 2024$0.73231.4M93.2M
Q1 2024$0.61195.9M76.8M
Q4 2023$0.66230.0M85.4M
Q3 2023$0.62216.0M81.8M
Halozyme Therapeutics (HALO) — Earnings